IO Biotech reports Q1 EPS (34c) vs (30c) last year

“IO Biotech (IOBT) continues to make meaningful progress developing novel cancer therapies that are designed to address significant unmet needs in melanoma and other hard-to-treat cancers, and we are thrilled to be recognized for our work by Fast Company as one of the most innovative companies in the world,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “This year, we remain focused on delivering our Phase 3 data, preparing a Biologics License Application and planning for commercialization of Cylembio, our potentially first-in-class, immune-modulatory, off-the-shelf therapeutic cancer vaccine.”